These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21359155)

  • 1. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Shetye GS; Choi KB; Kim CY; Franzblau SG; Cho S
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0028221. PubMed ID: 34097493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
    Davies GR; Nuermberger EL
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S65-74. PubMed ID: 18762154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
    Budha NR; Lee RB; Hurdle JG; Lee RE; Meibohm B
    Tuberculosis (Edinb); 2009 Sep; 89(5):378-85. PubMed ID: 19748318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.
    Lakshminarayana SB; Huat TB; Ho PC; Manjunatha UH; Dartois V; Dick T; Rao SP
    J Antimicrob Chemother; 2015 Mar; 70(3):857-67. PubMed ID: 25587994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.
    Aljayyoussi G; Jenkins VA; Sharma R; Ardrey A; Donnellan S; Ward SA; Biagini GA
    Sci Rep; 2017 Mar; 7(1):502. PubMed ID: 28356552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Models of Antituberculosis Drugs in Patients: A Systematic Critical Review.
    Otalvaro JD; Hernandez AM; Rodriguez CA; Zuluaga AF
    Ther Drug Monit; 2021 Feb; 43(1):108-115. PubMed ID: 32956238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.
    Mason AB; Dartois V
    Methods Mol Biol; 2021; 2314():715-731. PubMed ID: 34235677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
    Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
    Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.